Philadelphia, PA (January 31, 2017) – Oncoceutics, Inc. announced that the United States Patent and Trademark Office (USPTO) has reissued patent #8,673,923, for the use of the company’s lead molecule ONC201 to treat various brain cancers, to include the correct depiction of the chemical structure of the molecule. The previous version of the patent, issued to Penn State in March 2014 and exclusively licensed to Oncoceutics, contained an incorrect drawing of the chemical structure. The reissued patent, #RE46,290, maintains the original priority date of April 2011.
This reissuance confirms Oncoceutics’ exclusive right to use ONC201 in the treatment of various brain tumors, including glioblastoma. Combined with other patents that have already issued, all of which include a correctly drawn structure, Oncoceutics possesses a robust IP portfolio for ONC201, including protection for a wide range of malignancies. The first patent in this portfolio does not expire until 2034, with various options for extensions.
In June 2016, the U.S. Food and Drug Administration (FDA) granted orphan drug designation to ONC201 for the treatment of glioblastoma, which provides additional market exclusivity.
The decision by the USPTO to reissue the patent resolves any confusion that was created by the publication in Angewandte Chemie International Edition entitled “Pharmacophore Reassignment for Induction of the Immunosurveillance Cytokine TRAIL” in May 2014 that pointed out that the March 2014 patent contained an incorrect drawing of the ONC201 chemical structure.
“Oncoceutics has always maintained that the relevant discovery was that ONC201 has unexpected activity against human cancer,” said Martin Stogniew, PhD, Chief Development Officer of Oncoceutics. “The chemical structure included in the patent is simply a means to depict ONC201. Therefore, the USPTO agreed that the drawing of the chemical structure could be corrected to better reflect that discovery.”
ONC201 is the founding member of the imipridone family and has demonstrated excellent anti-cancer activity and safety in preclinical models. The drug is currently being investigated in five clinical trials, including an ongoing Phase II study in patients with recurrent glioblastoma at the Dana Farber Cancer Institute and Massachusetts General Hospital.
Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class of compounds that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers. The company recently completed a successful Phase I study in solid tumors and has begun additional Phase I/II and Phase II clinical programs in both solid and hematological malignancies. Oncoceutics and collaborative groups have received more than $7 million in grants over the last two years, including grants from the National Cancer Institute, the U.S. Food and Drug Administration, the Pennsylvania Department of Health, and The Musella Foundation. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements between Oncoceutics and leading comprehensive cancer centers, including The University of Texas MD Anderson Cancer Center and the Fox Chase Cancer Center. The company has established a robust intellectual property position, including several issued patents.
Contact Rohinton Tarapore for more information.